The Spotlight on Immuno-Oncology conference will feature speakers touching on a variety of topics including, but not limited to, novel CAR designs and approaches beyond B-Cell malignancies, genome and epigenome editing, and direct in vivo delivery for cancer immunotherapy. This program aims to transcend the basics of cell therapy and CAR T cells and dig deeper into gene engineering and the intersection of gene and cell therapy in this space. We believe this program will spark new conversations and breakthroughs in immuno-oncology.
Abstract submission open through Friday, June 2, at 11:59 p.m. (PT)!
If you're conducting research related to any of the topics below, send us your abstract today:
-
Novel CAR Designs and Approaches
-
B-Cell Malignancies and Beyond
-
TCR-Based Cancer Immunotherapy
-
Beyond T Cells
-
Genome and Epigenome Editing
-
Direct In Vivo Delivery for Cancer Immunotherapy
Submit your abstract
NOTE: The agenda for this event is in development. Updates will be made to this page as speakers are confirmed.
Tuesday, August 1
B-Cell Malignancies and Beyond
Mike Jensen, MD
Seattle Children's Research Institute
Manufacturing Process Modulates CAR T Cell Efficacy and Fitness in Pediatric Subjects
Carl June, MD
University of Pennsylvania
CAR T Cell Clinical Trials
Rayne Rouce, MD
Baylor College of Medicine
CAR T for T-Cell Malignancies
TCRs
Chiara Bonini, MD
Vita-Salute San Raffaele University
TCR and Inhibitory Receptor Genome Editing
Aude Chapuis, MD
Fred Hutchinson Cancer Research Center
Chris Klebanoff, MD
Memorial Sloan Kettering Cancer Center
Neo-AG TCR
Dirk Busch, MD
Technical University of Munich
Direct In Vivo Delivery
Saar Gill, MBBS, PhD, FRACP
University of Pennsylvania
CAR T Cell Targeting In Vivo
Wednesday, August 2
Genome and Epigenome Editing for Cancer Immunotherapy
Pietro Genovese, PhD
Harvard Medical School
Clonal Tracking of Gene Edited Cells
Justin Eyquem, PhD
UCSF
Novel AAV Variants Enabling Gene Targeting for Experimental T Cell Immunology
Jamie Schafer, PhD
Chroma Medicine
Using Epigenetic Editing to Engineer CAR T Cells
Beyond T Cells
Paula Cannon, PhD
University of Southern California
Bob Valamehr, PhD
Fate Therapeutics, Inc.
IPSC-Derived Cells
Michael Hudecek, MD
University Hospital Wurzburg
Minicircles & Transposon for T Cell Production
Catherine Bollard, MD
The George Washington University
Native T-Cells for Adoptive Cell Therapy
Support the Conference
Download the prospectus below and contact development@asgct.org if you're interested in learning more about how your company can support this event.
.aspx?width=350&height=350)